knowledge -WSS

knowledge

author：knowledge 2025-09-30 22:10:50 - browse：68363

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How AI helped researchers track recovery from depression

WSS

Focused ultrasound for uterine fibroids: an uphill battle

Average age of first period drops to 11.9 years, study shows

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

First Opinion Podcast: What happens when kids become caregivers?

iTeos Therapeutics debuts first data on TIGIT

Adam's Biotech Scorecard: Do Sarepta's exon

Wikipedia

knowledge

hotspot

Apple is now the first public company to be valued at $3 trillion

AI used to predict Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AI used to predict Covid

Affirmative action in medical school literally saved lives

Insmed lung disease drug hits target in key Phase 3 trial

Medicare proposal to cover medical devices draws a mixed reaction

Experts study whether long Covid risk adds up with each reinfection

Medicare details structure of new drug price negotiation program

David Sabatini, ex

focus

Adam's Biotech Scorecard: Do Sarepta's exon

Lasker Awards 2023: Winners in biomedical research

Senate HELP committee spars over health care workforce policies

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

CommonSpirit Health keeps growing, even as it loses money

FDA panel to weigh approval of NurOwn, controversial ALS drug

Wikipedia

focus

focus

explore